September 3, 2020 08:19 AM EDTUpdated 10:43 AM

Akebia shares MACEd as their PhIII anemia drug fails on safety, offering rival FibroGen a huge advantage

John Carroll

Editor & Founder

Nicole DeFeudis

Editor

Akebia $AKBA slammed directly into an unexpected brick wall Thursday morning, as the biotech reported a critical failure in its second Phase III study of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Akebia shares MACEd as their PhIII anemia drug fails on safety, offering rival FibroGen a huge advantage

John Carroll

Editor & Founder

Nicole DeFeudis

Editor

Sign up to read this article for free.

Pfizer looking to sell hospital drugs unit — reports

'Expertise is a real thing': FDA commissioner warns of political risk to agency

AstraZeneca CEO reaffirms commitment to China following executive's detention

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Ake­bia shares MACEd as their PhI­II ane­mia drug fails on safe­ty, of­fer­ing ri­val Fi­bro­Gen a huge ad­van­tage

Editor & Founder

Editor

Sign up to read this article for free.

Akebia shares MACEd as their PhIII anemia drug fails on safety, offering rival FibroGen a huge advantage